Morphine

Generic Name: Morphine

Brand Names: Arymo, Avinza, Doloral, Duramorph, Embeda, Infumorph, Kadian, M-ediat, M-eslon, MSIR, Mitigo, Ms Contin, Statex

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₁₉NO_₃

CAS Number: 57-27-2

Unique Ingredient Identifier: 76I7G6D29C

Background: Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as codeine, fentanyl, methadone, hydrocodone, hydromorphone, meperidine, and oxycodone.

Morphine was granted FDA approval in 1941.

Indication: Morphine is used for the management of chronic, moderate to severe pain.

Opiods, including morphine, are effective for the short term management of pain. Patients taking opioids long term may need to be monitored for the development of physical dependence, addiction disorder, and drug abuse.

Associated Conditions: Chronic Pain, Severe Pain

Associated Therapies: -

Clinical Trials

A Comparison of Analgesic Efficacy Between a Single Dose of ORG 28611, Morphine, and Placebo After Dental Impaction Surgery (Study P05800)

Phase 2

Terminated

Conditions: Analgesia

Interventions: Drug: Placebo
Drug: Org 28611
Drug: morphine sulfate

First Posted Date: 2008-10-31

Last Posted Date: 2015-09-14

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 11

Registration Number: NCT00782951

Intraoperative and Postoperative Analgesia for Laparoscopic Surgery.

Phase 4

Completed

Conditions: Analgesia

Interventions: Drug: general anesthesia (fentanyl)
Drug: morphine
Drug: intrathecal analgesia (morphine)

First Posted Date: 2008-10-15

Last Posted Date: 2010-09-22

Lead Sponsor: Rambam Health Care Campus

Target Recruit Count: 40

Registration Number: NCT00772187

Locations: 🇮🇱
Rambam Health Care Campus, Haifa, Israel

Methadone in Pediatric and Adult Sickle Cell Patients

Not Applicable

Completed

Conditions: Sickle Cell Disease

Interventions: Drug: Methadone
Drug: Morphine

First Posted Date: 2008-09-26

Last Posted Date: 2020-01-22

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 47

Registration Number: NCT00761085

Locations: 🇺🇸
Barnes Jewish Hospital/St. Louis Children's Hospital, Saint Louis, Missouri, United States

Comparison of One Morphine Sulfate Sustained-Release 200mg Capsule With Two 100 mg KADIAN Capsules Under Fed Conditions

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: morphine sulfate sustained-release capsules
Drug: KADIAN

First Posted Date: 2008-09-25

Last Posted Date: 2010-08-17

Lead Sponsor: Actavis Inc.

Target Recruit Count: 36

Registration Number: NCT00759356

Locations: 🇺🇸
CEDRA Clinical Research, LLC, Austin, Texas, United States

Study to Determine the Bioavailability, Pharmacodynamic Effects, and Safety of Whole and Crushed ALO-01 Compared to Morphine Sulfate Immediate Release (MSIR)

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: ALO-01
Drug: MSIR
Drug: Placebo

First Posted Date: 2008-09-12

Last Posted Date: 2013-09-16

Lead Sponsor: Pfizer

Target Recruit Count: 32

Registration Number: NCT00751478

Locations: 🇨🇦
DecisionLine Clinical Research, Toronto, Ontario, Canada

Hormone Function in Men Treated for Pain With Opioids or Placebo

Phase 4

Completed

Conditions: Osteoarthritis
Chronic Pain

Interventions: Drug: Placebo
Drug: MS Contin

First Posted Date: 2008-08-20

Last Posted Date: 2015-04-29

Lead Sponsor: National Institute of Nursing Research (NINR)

Target Recruit Count: 8

Registration Number: NCT00737737

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Effect of Early Morphine Administration on the Development of Acute Opioid Tolerance During Pediatric Scoliosis Surgery

Phase 3

Completed

Conditions: Scoliosis

Interventions: Other: Saline
Drug: Morphine

First Posted Date: 2008-08-20

Last Posted Date: 2014-11-19

Lead Sponsor: The Hospital for Sick Children

Target Recruit Count: 40

Registration Number: NCT00737997

Locations: 🇨🇦
The Hospital for Sick Children, Toronto, Ontario, Canada

Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer

Not Applicable

Terminated

Conditions: Chronic Myeloproliferative Disorders
Brain and Central Nervous System Tumors
Leukemia
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Neoplasms
Pain
Precancerous Condition
Unspecified Adult Solid Tumor, Protocol Specific
Lymphoma
Lymphoproliferative Disorder

Interventions: Drug: methadone hydrochloride
Drug: morphine sulfate
Drug: oxycodone hydrochloride

First Posted Date: 2008-08-01

Last Posted Date: 2020-09-24

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 1

Registration Number: NCT00726830

Locations: 🇺🇸
Palmetto Hematology Oncology, PC at Gibbs Regional Cancer Center, Spartanburg, South Carolina, United States
🇺🇸
M. D. Anderson Cancer Center at University of Texas, Houston, Texas, United States